These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2022 related articles for article (PubMed ID: 33617828)

  • 1. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.
    Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS
    Front Immunol; 2021; 12():737076. PubMed ID: 34659228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report.
    Nakamura M; Ueno M; Hayami S; Kawai M; Miyamoto A; Suzaki N; Hirono S; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Kojima F; Yamaue H
    Anticancer Res; 2020 Jul; 40(7):4123-4129. PubMed ID: 32620661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma.
    Chen F; Sheng J; Li X; Gao Z; Zhao S; Hu L; Chen M; Fei J; Song Z
    Biomed Pharmacother; 2024 Jun; 175():116659. PubMed ID: 38692063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
    Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
    Front Immunol; 2021; 12():705378. PubMed ID: 34526987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications.
    Yu F; Gong L; Mo Z; Wang W; Wu M; Yang J; Zhang Q; Li L; Yao J; Dong J
    Biosci Trends; 2019 Mar; 13(1):58-69. PubMed ID: 30773525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion.
    Ye Y; Zhou L; Xie X; Jiang G; Xie H; Zheng S
    J Surg Oncol; 2009 Nov; 100(6):500-4. PubMed ID: 19697355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma.
    Lomphithak T; Akara-Amornthum P; Murakami K; Hashimoto M; Usubuchi H; Iwabuchi E; Unno M; Cai Z; Sasano H; Jitkaew S
    Sci Rep; 2021 Jun; 11(1):11743. PubMed ID: 34083572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients.
    Kitano Y; Yamashita YI; Nakao Y; Itoyama R; Yusa T; Umezaki N; Tsukamoto M; Yamao T; Miyata T; Nakagawa S; Okabe H; Imai K; Chikamoto A; Ishiko T; Baba H
    Ann Surg Oncol; 2020 Feb; 27(2):599-607. PubMed ID: 31407173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
    Supimon K; Sangsuwannukul T; Sujjitjoon J; Chieochansin T; Junking M; Yenchitsomanus PT
    Cytotherapy; 2023 Feb; 25(2):148-161. PubMed ID: 36396553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
    Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
    Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies Against Immune Checkpoint Molecules Restore¬†Functions of Tumor-Infiltrating T Cells in Hepatocellular¬†Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma.
    Sato Y; Kinoshita M; Takemura S; Tanaka S; Hamano G; Nakamori S; Fujikawa M; Sugawara Y; Yamamoto T; Arimoto A; Yamamura M; Sasaki M; Harada K; Nakanuma Y; Kubo S
    Pathol Int; 2017 Mar; 67(3):163-170. PubMed ID: 28139862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma.
    Sun BY; Zhang D; Gan W; Wu JF; Wang ZT; Sun GQ; Zhou J; Fan J; Yi Y; Hu B; Zhang BH; Qiu SJ
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):348. PubMed ID: 39002018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation.
    Roberts A; Bentley L; Tang T; Stewart F; Pallini C; Juvvanapudi J; Wallace GR; Cooper AJ; Scott A; Thickett D; Lugg ST; Bancroft H; Hemming B; Ferris C; Langman G; Robinson A; Chapman J; Naidu B; Pinkney T; Taylor GS; Brock K; Stamataki Z; Brady CA; Curnow SJ; Gordon J; Qureshi O; Barnes NM
    Sci Rep; 2021 Feb; 11(1):4030. PubMed ID: 33597595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
    Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 102.